Teva Sues Dr. Reddy’s For Copaxone Patent Infringement

August 11, 2014 | Teva announced that it will sue Indian pharmaceutical company Dr. Reddy’s for a generic version of three-times-a-week Copaxone 40 mg/mL treatment. Copaxone is a drug used to treat multiple sclerosis approved by the Food & Drug Administration in the United States. Teva plans to file a lawsuit against Dr. Reddy’s for patent infringement within 45 days, the allotted amount of time according to the Hatch-Waxman Act in the United States. Teva asserts that Copaxone is protected by two Orange Book patents that remain in effect until 2030. Teva is an international pharmaceutical company headquartered in Petach Tikvah, Israel specializing in the creation of generic and proprietary pharmaceuticals and active pharmaceutical ingredients.